If lymph node involvement is verified in a patient undergoing neoadjuvant therapy that is a potential prospect for targeted axillary dissection (TAD), a marker must be inserted within the lymph node after biopsy. There have been no clinically related alterations as compared to 2011 aside from new info and https://wessext642nuc9.fare-blog.com/profile